Sarepta Therapeutics, Inc.
SRPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.34 | 0.60 | -0.29 | 0.63 |
| FCF Yield | -2.96% | -6.60% | -3.14% | -6.58% |
| EV / EBITDA | 35.43 | -22.49 | -20.61 | -20.71 |
| Quality | ||||
| ROIC | 6.06% | -10.09% | -21.66% | -16.68% |
| Gross Margin | 83.22% | 87.91% | 85.00% | 86.17% |
| Cash Conversion Ratio | -0.87 | 0.93 | 0.46 | 1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | 26.80% | 21.00% | 19.99% | 22.61% |
| Free Cash Flow Growth | 41.74% | -65.18% | 26.05% | -2,006.52% |
| Safety | ||||
| Net Debt / EBITDA | 0.72 | -2.20 | -1.12 | 3.19 |
| Interest Coverage | 11.86 | -12.17 | -10.07 | -7.08 |
| Efficiency | ||||
| Inventory Turnover | 0.43 | 0.47 | 0.69 | 0.52 |
| Cash Conversion Cycle | 737.24 | 512.53 | 383.43 | 500.97 |